They're both anti-IL-1β agents, but failure of anakinra in adult-onset Still's Disease doesn't mean canakinumab might not work (and work quickly) - see row 7-10 below. Anyone else have that experience? Corrado @Giacomo97811458, San Raffaele Hosp, Milan #ACR19 ABST1245 @RheumNow https://t.co/2qQK08apnT